AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Significant Growth in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the target of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 7,013,343 shares, a growth of 5,016.3% from the May 14th total of 137,078 shares. Based on an average daily trading volume, of 123,199,850 shares, the short-interest ratio is presently 0.1 days. Approximately 48.2% of the shares of the company are short sold.

AIM ImmunoTech Stock Performance

NYSEAMERICAN:AIM traded down $0.12 on Tuesday, reaching $0.40. 10,626,895 shares of the company’s stock were exchanged, compared to its average volume of 17,777,662. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01. The firm has a market cap of $5.87 million, a price-to-earnings ratio of -0.06 and a beta of 1.18. AIM ImmunoTech has a 52 week low of $0.21 and a 52 week high of $20.35. The stock has a fifty day simple moving average of $0.49 and a 200-day simple moving average of $0.92.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its earnings results on Friday, May 15th. The company reported ($0.69) earnings per share for the quarter. The business had revenue of $0.02 million for the quarter. As a group, sell-side analysts predict that AIM ImmunoTech will post -0.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets decreased their price objective on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $9.00.

Hedge Funds Weigh In On AIM ImmunoTech

A number of large investors have recently modified their holdings of the company. Corient Private Wealth LLC bought a new position in shares of AIM ImmunoTech in the second quarter valued at approximately $87,000. DRW Securities LLC boosted its position in shares of AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after acquiring an additional 26,254 shares during the period. Finally, Sabby Management LLC bought a new position in shares of AIM ImmunoTech in the third quarter valued at approximately $79,000. 12.02% of the stock is currently owned by institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.